These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

916 related items for PubMed ID: 32381564

  • 21. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W.
    Arthritis Res Ther; 2024 Feb 15; 26(1):50. PubMed ID: 38360699
    [Abstract] [Full Text] [Related]

  • 22. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
    Mourad A, Gniadecki R.
    J Rheumatol; 2020 Jan 15; 47(1):59-65. PubMed ID: 30824641
    [Abstract] [Full Text] [Related]

  • 23. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.
    Ann Rheum Dis; 2014 Mar 15; 73(3):529-35. PubMed ID: 24401994
    [Abstract] [Full Text] [Related]

  • 24. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L, Ingrid E, Sepriano A, Nikiphorou E, Østgård R, Lauper K, Grosse-Michaelis I, Kloppenburg M, Glintborg B, Liew DFL, Kragstrup TW.
    Drug Saf; 2024 Nov 15; 47(11):1075-1093. PubMed ID: 39012469
    [Abstract] [Full Text] [Related]

  • 25. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
    Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS.
    Ann Rheum Dis; 2024 May 15; 83(6):706-719. PubMed ID: 38499325
    [Abstract] [Full Text] [Related]

  • 26. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P, Thongprayoon C, Davis JM.
    Semin Arthritis Rheum; 2016 Feb 15; 45(4):428-38. PubMed ID: 26610638
    [Abstract] [Full Text] [Related]

  • 27. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis.
    Bilal J, Riaz IB, Kamal MU, Elyan M, Sudano D, Khan MA.
    J Clin Rheumatol; 2018 Jan 15; 24(1):6-13. PubMed ID: 28926467
    [Abstract] [Full Text] [Related]

  • 28. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
    Leung YY, Korotaeva TV, Candia L, Pedersen SJ, Bautista Molano W, Ruderman EM, Bisoendial R, Perez-Alamino R, Olsder W, Möller B, Grazio S, Gudu T, Mody GM, Pineda C, Raffayova H, Rohekar S, Goldenstein-Schainberg C, Gutierrez Urena SR, Casasola Vargas JC, Meghnathi B, Prasad R, Richette P, Miranda JRS, Malliotis N, Lindqvist U, Simon D, Ezeonyeji A, Soriano ER, FitzGerald O.
    J Rheumatol; 2023 Jan 15; 50(1):119-130. PubMed ID: 36243409
    [Abstract] [Full Text] [Related]

  • 29. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.
    Ravindran V, Scott DL, Choy EH.
    Ann Rheum Dis; 2008 Jun 15; 67(6):855-9. PubMed ID: 17827183
    [Abstract] [Full Text] [Related]

  • 30. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P, Thongprayoon C, Davis JM.
    Clin Rheumatol; 2016 Jul 15; 35(7):1795-803. PubMed ID: 26852316
    [Abstract] [Full Text] [Related]

  • 31. Switching biologics in the treatment of psoriatic arthritis.
    Merola JF, Lockshin B, Mody EA.
    Semin Arthritis Rheum; 2017 Aug 15; 47(1):29-37. PubMed ID: 28363434
    [Abstract] [Full Text] [Related]

  • 32. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT, DISCOVER-1 Study Group.
    Lancet; 2020 Apr 04; 395(10230):1115-1125. PubMed ID: 32178765
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, Ramiro S, van der Heijde D, Nikiphorou E.
    Ann Rheum Dis; 2023 Jan 04; 82(1):130-141. PubMed ID: 36270657
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Emerging treatment options for spondyloarthritis.
    Torgutalp M, Poddubnyy D.
    Best Pract Res Clin Rheumatol; 2018 Jun 04; 32(3):472-484. PubMed ID: 31171316
    [Abstract] [Full Text] [Related]

  • 37. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
    Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS.
    Nat Rev Rheumatol; 2016 Dec 04; 12(12):743-750. PubMed ID: 27829672
    [Abstract] [Full Text] [Related]

  • 38. Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.
    Kristensen LE, Ng KJ, Ngantcha M, Morel J, Lubrano E, Tillett W, Alten R, Chandran V, Martinez Ferrer À, Zhu B, Kennedy D, Holzkämper T, Gullick N, Kronbergs A, Fakhouri W, de la Torre I, McGonagle DG.
    RMD Open; 2024 Sep 20; 10(3):. PubMed ID: 39306343
    [Abstract] [Full Text] [Related]

  • 39. Novel Therapeutic Approaches and Treatment Targets for Psoriatic Arthritis.
    Benfaremo D, Paci V, Luchetti MM, Gabrielli A.
    Curr Pharm Biotechnol; 2021 Sep 20; 22(1):85-98. PubMed ID: 32988348
    [Abstract] [Full Text] [Related]

  • 40. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
    Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B.
    Ann Rheum Dis; 2014 Feb 20; 73(2):414-9. PubMed ID: 23355079
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.